CO4910170A1 - Vacunas - Google Patents
VacunasInfo
- Publication number
- CO4910170A1 CO4910170A1 CO97057863A CO97057863A CO4910170A1 CO 4910170 A1 CO4910170 A1 CO 4910170A1 CO 97057863 A CO97057863 A CO 97057863A CO 97057863 A CO97057863 A CO 97057863A CO 4910170 A1 CO4910170 A1 CO 4910170A1
- Authority
- CO
- Colombia
- Prior art keywords
- virus
- composition
- adjuvant
- herpes simplex
- vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 abstract 4
- 239000002671 adjuvant Substances 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 241000588807 Bordetella Species 0.000 abstract 1
- 241000589968 Borrelia Species 0.000 abstract 1
- 241000606161 Chlamydia Species 0.000 abstract 1
- 241000282324 Felis Species 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 abstract 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 abstract 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 abstract 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 241000701806 Human papillomavirus Species 0.000 abstract 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
- 208000016604 Lyme disease Diseases 0.000 abstract 1
- 201000009906 Meningitis Diseases 0.000 abstract 1
- 241000588653 Neisseria Species 0.000 abstract 1
- 208000030852 Parasitic disease Diseases 0.000 abstract 1
- 241000224016 Plasmodium Species 0.000 abstract 1
- 241000607142 Salmonella Species 0.000 abstract 1
- 229930182558 Sterol Natural products 0.000 abstract 1
- 241000223996 Toxoplasma Species 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 229940037003 alum Drugs 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 208000005252 hepatitis A Diseases 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 201000010284 hepatitis E Diseases 0.000 abstract 1
- 230000007813 immunodeficiency Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 150000003432 sterols Chemical class 0.000 abstract 1
- 235000003702 sterols Nutrition 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
- C12N2740/11034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9620795.6A GB9620795D0 (en) | 1996-10-05 | 1996-10-05 | Vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4910170A1 true CO4910170A1 (es) | 2000-04-24 |
Family
ID=10800990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO97057863A CO4910170A1 (es) | 1996-10-05 | 1997-10-03 | Vacunas |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0939650A1 (fr) |
| JP (1) | JP2001501640A (fr) |
| KR (1) | KR20000048866A (fr) |
| CN (1) | CN1238696A (fr) |
| AR (1) | AR009958A1 (fr) |
| AU (1) | AU714930B2 (fr) |
| BR (1) | BR9711853A (fr) |
| CA (1) | CA2267191A1 (fr) |
| CO (1) | CO4910170A1 (fr) |
| CZ (1) | CZ116799A3 (fr) |
| GB (1) | GB9620795D0 (fr) |
| HU (1) | HUP9904549A3 (fr) |
| IL (1) | IL128985A0 (fr) |
| NO (1) | NO991524L (fr) |
| NZ (1) | NZ334734A (fr) |
| PL (1) | PL332633A1 (fr) |
| TR (1) | TR199900729T2 (fr) |
| WO (1) | WO1998015287A1 (fr) |
| ZA (1) | ZA978868B (fr) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE435661T1 (de) * | 1997-08-29 | 2009-07-15 | Antigenics Inc | Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel |
| GB9718901D0 (en) * | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| GB9817052D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| EP1126876B1 (fr) * | 1998-10-16 | 2007-03-21 | GlaxoSmithKline Biologicals S.A. | Produits d'addition et vaccins |
| JP3282603B2 (ja) | 1999-01-28 | 2002-05-20 | 株式会社微生物化学研究所 | アジュバントおよびそれを用いたワクチン |
| AU769539B2 (en) | 1999-01-29 | 2004-01-29 | Zoetis Services Llc | Adjuvants for use in vaccines |
| GB9909077D0 (en) * | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
| US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
| DE60014076T2 (de) | 1999-04-19 | 2005-10-13 | Glaxosmithkline Biologicals S.A. | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid |
| GB9921147D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| AU768851B2 (en) | 1999-09-24 | 2004-01-08 | Nihon Nohyaku Co., Ltd. | Aromatic diamide derivatives or salts thereof, agricultural/horticultural chemicals and method of using the same |
| CA2721011A1 (fr) | 1999-10-22 | 2001-05-03 | Aventis Pasteur Limited | Molecule gp100 modifiee et ses applications |
| EP1239876B1 (fr) * | 1999-11-19 | 2008-07-30 | Csl Limited | Compositions vaccinales hcv |
| US6905712B2 (en) | 1999-12-08 | 2005-06-14 | Statens Veterinarmedicinska Anstalt | Vaccine adjuvants comprising ginseng plant extract and added aluminum salt |
| WO2001041802A1 (fr) * | 1999-12-08 | 2001-06-14 | Statens Veterinärmedicinska Anstalt | Adjuvants de vaccins comportant de l'extrait vegetal de ginseng et un sel d'aluminium |
| WO2001085932A2 (fr) | 2000-05-10 | 2001-11-15 | Aventis Pasteur Limited | Polypeptides immunogeniques codes par des minigenes mage et leurs utilisations |
| PT1326638E (pt) | 2000-10-18 | 2008-02-06 | Glaxosmithkline Biolog Sa | Vacinas contra cancros |
| EP1361890B1 (fr) * | 2001-02-23 | 2011-03-30 | GlaxoSmithKline Biologicals s.a. | Formulations de vaccins contre la grippe dispositif pour administration intradermique |
| CA2438960A1 (fr) * | 2001-02-23 | 2002-09-06 | Glaxosmithkline Biologicals S.A. | Nouveau vaccin |
| GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
| GB0123580D0 (en) * | 2001-10-01 | 2001-11-21 | Glaxosmithkline Biolog Sa | Vaccine |
| CA2484941A1 (fr) | 2002-07-24 | 2004-02-05 | Intercell Ag | Antigenes a phase de lecture alternante a partir de virus |
| AU2003258672B2 (en) | 2002-09-13 | 2008-10-30 | Intercell Ag | Method for isolating hepatitis C virus peptides |
| EP2277533B1 (fr) | 2002-10-23 | 2016-07-20 | GlaxoSmithKline Biologicals S.A. | Methodes de vaccination contre le paludisme |
| ES2351489T3 (es) * | 2003-03-24 | 2011-02-07 | Intercell Ag | Vacunas mejoradas. |
| EP2345420B1 (fr) | 2003-03-24 | 2016-01-06 | Valneva Austria GmbH | Utilisation d'un adjuvant induisant une réponse immunitaire du type TH1 pour renforcer des réponses immunitaires |
| GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| GB0503337D0 (en) | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
| GB0513421D0 (en) | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| GB0519871D0 (en) | 2005-09-30 | 2005-11-09 | Secr Defence | Immunogenic agents |
| US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| US10842867B2 (en) | 2005-11-04 | 2020-11-24 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| SI1962899T1 (sl) | 2005-12-22 | 2011-11-30 | Glaxosmithkline Biolog Sa | Pnevmokokna polisaharidna konjugatna vakcina |
| EP2476433A1 (fr) | 2006-03-30 | 2012-07-18 | GlaxoSmithKline Biologicals S.A. | Composition immunogène |
| KR20090092752A (ko) | 2006-07-18 | 2009-09-01 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 말라리아 백신 |
| EP2040744B1 (fr) | 2006-07-25 | 2016-03-09 | The Secretary of State for Defence | Souche de vaccin vivant |
| ES2630205T3 (es) * | 2006-11-20 | 2017-08-18 | Duecom | Uso de partículas que contengan lípidos que comprenden saponínas quillaja para el tratamiento del cáncer |
| CA2896131C (fr) | 2007-03-02 | 2020-04-07 | Glaxosmithkline Biologicals S.A. | Nouveau procede et nouvelles compositions |
| ES2626662T3 (es) | 2007-06-26 | 2017-07-25 | Glaxosmithkline Biologicals S.A. | Vacuna que comprende conjugados de polisacárido capsular de Streptococcus pneumoniae |
| UY31285A1 (es) | 2007-08-13 | 2009-03-31 | Vacunas | |
| WO2009117035A1 (fr) | 2007-12-19 | 2009-09-24 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Formes solubles de la glycoprotéine f des virus hendra et nipah et leurs utilisations |
| GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
| GB0900455D0 (en) | 2009-01-13 | 2009-02-11 | Secr Defence | Vaccine |
| GB0901423D0 (en) | 2009-01-29 | 2009-03-11 | Secr Defence | Treatment |
| GB0901411D0 (en) | 2009-01-29 | 2009-03-11 | Secr Defence | Treatment |
| WO2010092479A2 (fr) | 2009-02-10 | 2010-08-19 | Novartis Ag | Vaccins contre la grippe comportant des quantités réduites de squalène |
| WO2010099580A1 (fr) | 2009-03-05 | 2010-09-10 | Jenny Colleen Mccloskey | Traitement d'une infection |
| GB0906234D0 (en) | 2009-04-14 | 2009-05-20 | Secr Defence | Vaccine |
| GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| EA201290956A1 (ru) | 2010-03-26 | 2013-04-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина против вич |
| US20130259948A1 (en) | 2010-09-21 | 2013-10-03 | National Institute Of Immunology | Spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles |
| WO2012041669A1 (fr) | 2010-09-27 | 2012-04-05 | Crucell Holland B.V. | Régime de vaccination de type amorce rappel hétérologue contre la malaria |
| SG10201701055WA (en) | 2011-09-16 | 2017-03-30 | Ucb Pharma Sa | Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile |
| WO2013074501A1 (fr) | 2011-11-14 | 2013-05-23 | Crucell Holland B.V. | Immunisation primovaccination-rappel hétérologue à l'aide de vaccins à base du virus de la rougeole |
| WO2015092710A1 (fr) | 2013-12-19 | 2015-06-25 | Glaxosmithkline Biologicals, S.A. | Administration simultanée controlatérale de vaccins |
| BR112019003462A2 (pt) | 2016-08-23 | 2019-06-25 | Glaxosmithkline Biologicals Sa | proteína de fusão, polinucleotídeo, vetor viral, composição farmacêutica, uso de uma proteína de fusão, polinucleotídeo, vetor viral ou composição farmacêutica, e, método para tratar ou prevenir infecção de hepatite b viral ou infecção de hepatite c viral |
| GB201614799D0 (en) | 2016-09-01 | 2016-10-19 | Glaxosmithkline Biologicals Sa | Compositions |
| WO2018060288A1 (fr) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions et méthodes de traitement d'une infection par hpv persistante |
| US10695424B2 (en) | 2016-12-07 | 2020-06-30 | Glaxosmithkline Biologicals S.A. | Method of making a liposome composition |
| GB201620968D0 (en) | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
| GB2577232B (en) | 2017-05-30 | 2022-07-06 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
| GB201721068D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
| GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
| MX2020013553A (es) | 2018-06-12 | 2021-02-26 | Glaxosmithkline Biologicals Sa | Polinucleotidos y polipeptidos de adenovirus. |
| BR112021000965A2 (pt) | 2018-08-07 | 2021-04-27 | Glaxosmithkline Biologicals S.A. | processos e vacinas |
| EP3897846A1 (fr) | 2018-12-21 | 2021-10-27 | GlaxoSmithKline Biologicals SA | Méthodes d'induction d'une réponse immunitaire |
| TW202102256A (zh) | 2019-03-05 | 2021-01-16 | 比利時商葛蘭素史密斯克藍生物品公司 | B型肝炎免疫法及組合物 |
| WO2023056117A1 (fr) * | 2021-10-02 | 2023-04-06 | Massachusetts Institute Of Technology | Combinaison synergique d'adjuvants de vaccins d'alun et de particule non-liposome, non micellaire |
| CN120456919A (zh) | 2022-12-19 | 2025-08-08 | 葛兰素史克生物有限公司 | 乙型肝炎组合物 |
| WO2024241172A2 (fr) | 2023-05-19 | 2024-11-28 | Glaxosmithkline Biologicals Sa | Procédés de déclenchement d'une réponse immunitaire contre une infection par le virus respiratoire syncycial et streptococcus pneumoniae |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9002314A (nl) * | 1990-10-23 | 1992-05-18 | Nederlanden Staat | Immunogene complexen, in het bijzonder iscoms. |
| US5585103A (en) * | 1991-07-25 | 1996-12-17 | Idec Pharmaceutical Corporation | Induction of cytotoxic T-lymphocyte responses |
| JP4129544B2 (ja) * | 1993-03-29 | 2008-08-06 | ファイザー・インク | サポニンアジュバント使用の多成分系クロストリジウム・ワクチン |
| UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
-
1996
- 1996-10-05 GB GBGB9620795.6A patent/GB9620795D0/en active Pending
-
1997
- 1997-09-30 HU HU9904549A patent/HUP9904549A3/hu unknown
- 1997-09-30 EP EP97910430A patent/EP0939650A1/fr not_active Withdrawn
- 1997-09-30 JP JP10517196A patent/JP2001501640A/ja active Pending
- 1997-09-30 KR KR1019990702874A patent/KR20000048866A/ko not_active Withdrawn
- 1997-09-30 BR BR9711853A patent/BR9711853A/pt not_active Application Discontinuation
- 1997-09-30 AU AU47812/97A patent/AU714930B2/en not_active Ceased
- 1997-09-30 CN CN97180166A patent/CN1238696A/zh active Pending
- 1997-09-30 CA CA002267191A patent/CA2267191A1/fr not_active Abandoned
- 1997-09-30 IL IL12898597A patent/IL128985A0/xx unknown
- 1997-09-30 WO PCT/EP1997/005578 patent/WO1998015287A1/fr not_active Application Discontinuation
- 1997-09-30 PL PL97332633A patent/PL332633A1/xx unknown
- 1997-09-30 CZ CZ991167A patent/CZ116799A3/cs unknown
- 1997-09-30 TR TR1999/00729T patent/TR199900729T2/xx unknown
- 1997-09-30 NZ NZ334734A patent/NZ334734A/xx unknown
- 1997-10-03 CO CO97057863A patent/CO4910170A1/es unknown
- 1997-10-03 ZA ZA978868A patent/ZA978868B/xx unknown
- 1997-10-03 AR ARP970104569A patent/AR009958A1/es unknown
-
1999
- 1999-03-29 NO NO991524A patent/NO991524L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA978868B (en) | 1999-04-06 |
| HU9904549A (en) | 2000-05-28 |
| CA2267191A1 (fr) | 1998-04-16 |
| KR20000048866A (ko) | 2000-07-25 |
| CZ116799A3 (cs) | 1999-08-11 |
| AR009958A1 (es) | 2000-05-17 |
| NO991524D0 (no) | 1999-03-29 |
| WO1998015287A1 (fr) | 1998-04-16 |
| EP0939650A1 (fr) | 1999-09-08 |
| BR9711853A (pt) | 1999-08-24 |
| GB9620795D0 (en) | 1996-11-20 |
| IL128985A0 (en) | 2000-02-17 |
| AU714930B2 (en) | 2000-01-13 |
| CN1238696A (zh) | 1999-12-15 |
| NZ334734A (en) | 2000-05-26 |
| HUP9904549A3 (en) | 2001-06-28 |
| PL332633A1 (en) | 1999-09-27 |
| JP2001501640A (ja) | 2001-02-06 |
| NO991524L (no) | 1999-03-29 |
| TR199900729T2 (xx) | 1999-07-21 |
| AU4781297A (en) | 1998-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4910170A1 (es) | Vacunas | |
| ES2164070T3 (es) | Inmunogenos quimericos. | |
| ES2150493T3 (es) | Adyuvantes para vacunas contra el virus sincitico respiratorio. | |
| ATE295895T1 (de) | Genetischer impfstoff gegen den immunschwäche virus | |
| DE60121136D1 (de) | Proteasom-influenzavirus-impfstoffzusammensetzung | |
| MY110086A (en) | Herpes simplex virus vaccines comrpising glycoprotein d and 3d-mpl | |
| AR020134A1 (es) | Antigenos inmunologicos contra el virus herpes simplex y metodos para el uso de los mismos | |
| CY1110585T1 (el) | ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ | |
| SI9300335B (sl) | Vakcinski sestavek,ki obsega 3-DE-O-aciliran monofosforni lipid A in QS21 | |
| SE9102976D0 (sv) | Hybrid dna vektorer, encelliga organismer och bakterier till anvaendning foer produktion av hiv-proteiner och peptider | |
| ES2157447T3 (es) | Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio. | |
| ES2134197T3 (es) | Vacunas contra el virus del herpes simplex vp16. | |
| DE69632235D1 (de) | Newcastle-Krankheitsvirus-Kombinationsimpfstoff | |
| CY1106785T1 (el) | Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο | |
| DK0830141T3 (da) | Forbedrede virusvacciner | |
| DE68927348D1 (de) | Künstlicher impfstoff gegen aids-virus | |
| RU2000116260A (ru) | Вакцины с адъювантом ltb | |
| IL106968A0 (en) | Potentiation of immunogenic response | |
| ES2035818T3 (es) | Mutantes de delecion de la timidin-kinasa del virus del herpes bovino-1, vacunas contra la rinotraqueitis bovina infecciosa que los contienen y metodos para su produccion y uso. | |
| UY26882A1 (es) | Nuevo tratamiento | |
| ES2127294T3 (es) | Vacunas del virus de la inmunodeficiencia anti-felino (fiv). | |
| AR004464A1 (es) | Un metodo para producir una proteina de capside de papilomavirus | |
| AR021414A1 (es) | Formulaciones conteniendo particulas semejantes a virus como inmunopotenciadores por via mucosal | |
| ES2141093T3 (es) | Herpesvirus equinos (ehv) que contienen adn ajeno, procedimiento para su obtencion y su empleo en vacunas. | |
| ATE221786T1 (de) | Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus |